Table 2 Comparison of baseline characteristics between responder and Non-Responder Groups.
Parameter | Responders (n = 14) | Non-responders (n = 18) | P-value |
|---|---|---|---|
Demographics | |||
Age (years), Mean ± SD | 61.2 ± 10.8 | 62.9 ± 12.3 | 0.686 |
Male, n (%) | 11 (78.6%) | 12 (66.7%) | 0.694 |
Etiology & Risk Factors | |||
HBV Infection, n (%) | 13 (92.9%) | 16 (88.9%) | 0.596 |
Significant Alcohol History, n (%) | 4 (28.6%) | 4 (22.2%) | 0.496 |
Liver Cirrhosis, n (%) | 6 (42.9%) | 6 (33.3%) | 0.718 |
Tumor Burden | |||
Number of Tumors (≥ 3), n (%) | 4 (28.6%) | 4 (22.2%) | 0.703 |
Max Tumor Diameter (≥ 10 cm), n (%) | 11 (78.6%) | 11 (61.1%) | 0.446 |
Cumulative Lesion Size (cm), Median (IQR) | 12.5 (10.3, 14.0) | 10.50 (8.0, 14.0) | 0.491 |
Macrovascular Invasion, n (%) | 4 (28.6%) | 6 (33.3%) | 0.541 |
Extrahepatic Metastasis, n (%) | 2 (14.3%) | 5 (27.8%) | 0.426 |
Disease Stage | |||
BCLC Stage (C), n (%) | 8 (57.1%) | 12 (66.7%) | 0.283 |
Child-Pugh Grade (B), n (%) | 6 (42.9%) | 10 (55.6%) | 0.483 |
Biomarkers | |||
Baseline AFP (≥ 400 ng/mL), n (%) | 8 (57.1%) | 14 (77.8%) | 0.267 |
Baseline AFP (ng/mL), Median (IQR) | 582.0 (189.0, 1343) | 671.0 (460.0, 1363) | 0.367 |
Immune Marker | |||
Baseline CD28⁻CD57⁺CD8⁺ %, Median (IQR) | 21.45 (16.10, 26.50) | 33.90 (24.63, 45.50) | 0.027 |
Treatment Information | |||
Cycles to First Assessment, Median (IQR) | 3.5 (3, 4) | 4 (3, 4) | 0.721 |
